IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$24.27 USD
-0.08 (-0.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $24.26 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IDYA 24.27 -0.08(-0.33%)
Will IDYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDYA
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Other News for IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA ...
IDEAYA Biosciences (IDYA) Price Target Raised by JP Morgan | IDYA Stock News
JPMorgan Raises Price Target for Ideaya Biosciences (IDYA) Amid Growth Potential
JPMorgan ups Ideaya target, adds to Analyst Focus List
IDEAYA Biosciences Announces Key Presentation at ESMO 2025 for Phase 2 Trial in Uveal Melanoma ...